Search Results

IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant IONTAS now seeking development partners

March 22, 2021

·

2 min read

Drug Development

IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, announces that F-star Therapeutics, Inc., has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.

June 29, 2021

·

1 min read

Business

IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics

Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline

March 8, 2021

·

1 min read

Genetown

IONTAS Announces Mammalian Display Licensing Agreement With Bristol Myers Squibb

IONTAS’ mammalian display technology facilitates the identification of high affinity developable full-length antibody libraries in the context of mammalian cells

October 13, 2020

·

2 min read

Business

IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes.

May 7, 2020

·

2 min read

Business

IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralizing Antibodies with Picomolar Potency

IONTAS and FairJourney Biologics, two leading antibody discovery Clinical Research Organisations that joined forces this year, announce the discovery of potent SARS-CoV2 neutralizing antibodies as potential therapeutics for COVID-19.

September 28, 2020

·

4 min read

IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia

IONTAS Limited (IONTAS), , has been informed that International Biotechnology Center (IBC) Generium has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL).

December 9, 2019

·

2 min read

IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimised Antibodies for Novel Cancer Targets

IONTAS Limited announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

December 3, 2019

·

2 min read

Business

IONTAS Announces New Antibody Optimisation Agreement With Teva Pharmaceuticals

IONTAS Limited announced an agreement with Teva Pharmaceuticals to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.

July 29, 2019

·

1 min read

IONTAS named Small Business of the Year at Cambridge News Business Excellence Awards 2019

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has won ‘Small Business of the Year’ category at the Cambridge News Business Excellence Awards 2019.

March 25, 2019

·

1 min read